Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients  by De Paula, Flavio M. et al.
Kidney International, Vol. 66 (2004), pp. 1232–1238
Clinical consequences of an individualized dialysate sodium
prescription in hemodialysis patients
FLAVIO M. DE PAULA, ALDO J. PEIXOTO, LUCIANO V. PINTO, DAVID DORIGO, PEDRO J.M. PATRICIO,
and SERGIO F.F. SANTOS
Division of Nephrology, State University of Rio de Janeiro, Rio de Janeiro, Brazil; Section of Nephrology, Yale University School of
Medicine, New Haven, Connecticut; Clinica de Nefrologia Santa Teresa, Rio de Janeiro, Rio de Janeiro, Brazil; and Division of
Informatics, State University of Rio de Janeiro, Rio de Janeiro, Brazil
Clinical consequences of an individualized dialysate sodium
prescription in hemodialysis patients.
Background. Predialysis plasma sodium (Na+) concentra-
tion is relatively constant in hemodialysis (HD) patients, and
a higher dialysate Na+ concentration can promote an increase
in the interdialytic fluid ingestion to achieve an individual’s os-
molar set point, and individualization of dialysate Na+ concen-
tration may improve interdialytic weight gain (IDWG), blood
pressure (BP), and HD-related symptoms.
Methods. Twenty-seven nondiabetic, non-hypotension prone
HD patients were enrolled in a single-blind crossover study.
Subjects underwent nine consecutive HD sessions with the
dialysate Na+ concentration set to 138 mEq/L (standard Na+
HD), followed by nine sessions wherein the dialysate Na+ was
set to match the patients average pre-HD plasma Na+ mea-
sured three times during the standard Na+ phase multiplied by
0.95 (individualized dialysate Na+ HD). Dry weight, dialysis
prescription, and medications were not modified during the six
weeks of the study.
Results. Pre-HD Na+ was similar in both periods of the study
(standard Na+ HD, 134.0 ± 1.4 mEq/L; individualized Na+ HD,
134.0 ± 1.5 mEq/L; P = 0.735). There was a significant decrease
in interdialytic weight gain (2.91 ± 0.87 kg vs. 2.29 ± 0.65 kg; P<
0.001), interdialytic thirst scores, and episodes of intradialytic
hypotension in the individualized Na+ period compared with
the standard phase. Pre-HD BP was lower in individualized
Na+ HD in patients with uncontrolled BP at baseline (N = 15),
but not in those with controlled BP at baseline (N = 12) (BP
−15.6/−6.5 mm Hg in uncontrolled vs. BP +6.4/+4.5 mm Hg
in controlled, P = <0.001 for systolic BP and P = <0.001 for
diastolic BP).
Conclusion. An individualized Na+ dialysate based on pre-
dialysis plasma Na+ levels decreases thirst, IDWG, HD-related
symptoms, and pre-HD BP (in patients with uncontrolled BP
at baseline).
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Interdialytic weight gain (IDWG) is a major concern in
chronic hemodialysis (HD) treatment [1, 2]. Large IDWG
leads to expansion of extracellular volume, which is the
major determinant of hypertension in HD patients [3].
Furthermore, an excessive IDWG may lead to patient
discomfort during HD because brisk ultrafiltration rates
are required in order to get the patient to his or her esti-
mated dry weight during the relatively short period of a
conventional HD session [4].
Current HD practices include setting the dialysate
sodium concentration to levels as high as 144 mEq/L to
prevent HD complications related to rapid osmolar shifts
during HD, and indeed, the use of high dialysate sodium
concentrations is effective in preventing such complica-
tions [5]. However, predialysis plasma sodium concentra-
tion is constant in HD patients, and these patients seem to
have an individual osmolar set point [6]; consequently, the
use of a dialysate Na+ concentration higher than plasma
could contribute to an increase in the interdialytic fluid
ingestion in the attempt to achieve this set point [7].
Control of dialysate sodium has been extensively used
in patients who have frequent hypotension during HD.
In most studies, the sodium dialysate concentration is set
to a high concentration at the beginning of HD and is
gradually decreased, a procedure called sodium profiling
[8]. However, little data exist in stable, non-hypotension
prone patients [9]. In these patients, the benefits of higher
dialysate sodium are often not necessary, and they may
suffer from complications of high sodium dialysis, such
as increased thirst, IDWG, and hypertension [10]. Be-
cause lower dialysate sodium dialysis was safely and ef-
fectively used in the past [10], and there is evidence to
suggest that it is well tolerated in patients undergoing
high efficiency dialysis [11, 12], we designed a study to
investigate the short-term consequences of an individual-
ized dialysate Na+ prescription based on pre-HD plasma
sodium concentration on HD treatment parameters and
complications.
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METHODS
Thirty-seven patients on HD for at least three months
were enrolled from a single dialysis unit. All patients
were receiving thrice weekly HD with volumetric dial-
ysis machines (SPS 1550; Baxter, Deerfield, IL, USA)
using bicarbonate-based dialysate and cellulose acetate
dialyzers (CA-150, CA-170, CA-210; Baxter). They were
in stable clinical condition, stable prescribed dry weight,
mean dialysis prescription (Kt/V) ≥1.2, and residual daily
urine output <500 mL/day. Diabetic patients were not in-
cluded in the study in order to avoid possible effects of
poor glucose control on measurements of plasma sodium.
The study protocol was approved by the ethics committee
of the State University of Rio de Janeiro, and all subjects
gave written informed consent.
Study design
This was a prospective, nonrandomized, single-blind,
crossover trial. The study was performed in two different
phases, with each subject used as his/her own control. Dry
weight, dialysis prescription, and medications were not
modified during the entire study except for the dialysate
sodium concentration.
In the first phase, patients were submitted to nine con-
secutive HD sessions with a standard dialysis prescrip-
tion of blood flow ≥300 mL/min and dialysate flow of
500 mL/min. The standard dialysate composition was:
bicarbonate 33 mEq/L, potassium 2.0 mEq/L, calcium
3.5 mEq/L, magnesium 1.0 mEq/L, chloride 109.5 mEq/L,
and acetate 3.0 mEq/L. The dialysate sodium concen-
tration was fixed at 138 mEq/L, which is the standard
concentration used in our dialysis facility. The pre and
post-HD plasma sodium concentration was determined
for each patient in three different dialysis sessions using
a direct ion selective electrode method (AVL 9180; AVL
Medical Instruments, Schaffhausen, Switzerland). The
sodium concentration of the dialysate was determined
by the same method, and was shown to be quite constant
(130.1 ± 0.6 mEq/L). Dialysate conductivity (13.7 ±
0.2 ms/cm) was used as reference for dialysate sodium
concentration.
In the second phase of the study, patients were sub-
jected again to nine consecutive HD sessions, but the
dialysate Na+ concentration was set to the mean of the
pre-HD Na+ concentration multiplied by the Donnan co-
efficient of 0.95 (individualized Na+). Only 27 of the 37
patients had a mean pre-HD Na+ lower than the mea-
sured standard dialysate Na+ concentration. Because the
measured dialysate Na+ concentration at a prescribed
dialysate Na+ concentration of 138 mEq/L was 130.1 ±
0.6 mEq/L, only patients in whom measured plasma Na+
multiplied by 0.95 was lower than 130 mEq/L were in-
cluded in the study analysis, and the remaining 10 subjects
were excluded. Patients were not aware of the modifica-
tion in the dialysate Na+ concentration. Due to a limita-
tion in the machines used, wherein the dialysate Na+ can
only be adjusted to even numbers (138, 136, 134 mEq/L,
etc.), the prescribed gradient was 1 mEq/L above the tar-
get in nine patients, and 1 mEq/L below in six patients.
Sodium concentration of the dialysate with −2 and –4 de-
crease from the standard concentration was proportional
to the reduction (128 ± 1 mEq/L and 126 ± 1 mEq/L,
respectively).
Pre-, intra-, and post-HD BP were measured us-
ing a mercury sphygmomanometer. Auscultatory mea-
surements followed standard clinical guidelines using
Korotkoff I and V sounds to indicate systolic and dias-
tolic BP, respectively. Subjects were classified as having
“controlled” or “uncontrolled” BP based on the aver-
age pre-HD systolic BP on the three dialysis sessions
of the third week of the first phase of the study (on
standardized dialysate Na+). “Uncontrolled BP” was de-
fined as pre-HD systolic BP >150 mm Hg or diastolic BP
>85 mm Hg regardless of the use of antihypertensive
drugs. These values have been shown to have the best
composite predictive ability for hypertension in HD
patients (true positive rate of 81% to 82% and false posi-
tive rate of 33% to 39% using an average 44-hour ambu-
latory BP >135/85 as the gold standard) [13]. Similarly,
“controlled BP” was defined as pre-HD BP ≤150/85 mm
Hg, also regardless of medication use. Differences in BP
control were based on the average BP for the three HD
sessions of the last week of each phase of the study.
Estimated dry weight was determined through stan-
dard clinical criteria. Ultrafiltration (UF) and IDWG
were determined based on changes in body weight be-
fore and after each HD session (UF), or between the end
of HD and return to the next session (IDWG). In order
to allow for better interpretation of clinical indices, we
corrected the UF to pre-HD weight, and the IDWG to
the estimated dry weight, thus obtaining measures that
were more relevant to each specific patient.
Dialysis-related hypotension and symptoms
(headache, cramps, nausea, and vomiting) were recorded
and analyzed as the number of occurrences during each
study phase. Hypotensive episodes were defined as rapid
changes in BP (within 15 minutes) accompanied by
symptoms requiring nursing interventions, or a brisk fall
in BP >40 mm Hg systolic or >20 mm Hg diastolic within
a 15-minute period regardless of symptoms or inter-
ventions. Interdialytic thirst scores (nil, mild, moderate,
and severe) were obtained by a written questionnaire
answered by the patients after each phase of the study.
Statistical analysis
We used paired Student t tests to compare continu-
ous variables between each study phase, and two-sample
Student t tests were used to compare hypertensive and
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normotensives subjects. Chi-square tests were used to
compare categorical variables. Pearson correlation coef-
ficients and simple linear regression were used to study
the relationship between different continuous variables.
P values <0.05 were considered statistically significant.
We used the statistical package SPSS/PC (SPSS, Inc.,
Chicago, IL, USA) for all calculations.
RESULTS
Twenty-seven (13 males and 14 females) out of 37 pa-
tients had a mean predialysis plasma sodium concentra-
tion adjusted by the Gibbs-Donnan factor lower than
the standard dialysate sodium concentration. The mean
age was 46 ± 14 years and subjects were on dialysis for
a median time of 17 months (range 3 to 153 months).
Racial distribution was 18 caucasian (67%) and nine
black (33%). Hypertension was the presumed cause of
the end-stage renal disease in 19 patients (70%), chronic
glomerulonephritis in six (22%), tubulointerstitial
disease in one (1%), and unknown in one patient (1%).
Twenty-three patients (85%) were taking antihyperten-
sive medications (mean 2.1 ± 0.6 drugs; range 1 to
3 drugs). Based on the criteria of Agarwal and Lewis
[13] described above, 12 subjects were classified as having
controlled BP, and 15 as having uncontrolled BP. Twenty-
three patients (85%) were receiving erythropoietin
(6000 ± 3328 U/wk); mean hematocrit was 34 ± 5%. The
average duration of each HD session was 4.1 ± 0.3 hours.
Predialysis plasma Na+ was similar in both periods of
the study (Table 1). The coefficient of variation of pre-HD
sodium concentration was 0.5% and 0.7% in the stan-
dard and individualized phases, respectively. Postdialysis
plasma Na+ decreased significantly in the individualized
Na+ HD, and the dialysate Na+ concentration was re-
duced by 3 ± 1 mEq/L (Na+ gradient) during the individ-
ualized phase. In fact, as a matter of protocol, there was
no gradient in the individualized phase of the study. There
was a significant decrease in IDWG, IDWG/estimated dry
weight ratio, UF, and UF/pre-HD weight ratio in the in-
dividualized Na+ HD (Table 1).
There were no significant differences in pre- and post-
HD blood pressure levels for the group taken as a whole
(Table 1). However, when we categorized patients as hav-
ing controlled or uncontrolled BP, it became apparent
that uncontrolled patients had a significant reduction in
systolic BP during the individualized Na+ phase (BP
−15.6/−6.5 mm Hg, P < 0.001 for systolic BP and P =
0.079 for diastolic BP), whereas controlled subjects had
a net, not statistically significant, increase in BP (BP
+6.4/+4.5 mm Hg, P = 0.296 for systolic BP and P <
0.001 for diastolic BP). These differences of response be-
tween subjects with controlled and uncontrolled BP were
clinically and statistically different (Table 2). Figure 1 de-
picts individual responses in controlled BP and uncon-
Table 1. Plasma Na+ concentration, dialysis parameters, and blood
pressure in the standard Na+ HD and in the individualized Na+ HD
Standard Na+ Individualized Na+ P
Pre HD Na+ mEq/L 134.0 ± 1.4 134.0 ± 1.5 0.725
Post HD Na+ mEq/L 135.9 ± 2.0 133.1 ± 2.6 <0.001
IDWG kg 2.91 ± 0.87 2.29 ± 0.87 <0.001
IDWG % 4.73 ± 1.19 3.75 ± 0.97 <0.001
UF kg 2.89 ± 1.01 2.37 ± 0.68 <0.001
UF % 4.59 ± 1.10 3.73 ± 0.88 <0.001
Pre HD SBP mm Hg 147 ± 19 146 ± 19 0.554
Pre HD DBP mm Hg 85 ± 13 85 ± 12 0.938
Pre HD PP mm Hg 63 ± 12 60 ± 13 0.305
Post HD SBP mm Hg 124 ± 15 123 ± 17 0.701
Post HD DBP mm Hg 73 ± 11 74 ± 9 0.605
Post HD PP mm Hg 50 ± 10 48 ± 12 0.239
UF, ultrafiltration; UF%, ultrafiltration/predialysis weight; IDWG, interdia-
lytic weight gain, IDWG%, IDWG/estimated dry weight; SBP, systolic blood
pressure; DBP, diastolic blood pressure; PP, pulse pressure. Mean ± SD of nine
consecutive dialysis sessions.
Table 2. Differences in achieved blood pressure between patients
with controlled and uncontrolled BP in standard Na+ HD and
individualized Na+ HD
Controlled BP Uncontrolled BP P
Number of patients 12 15
Pre-HD SBP 1 mm Hg 130 ± 11 165 ± 15 <0.001
Pre-HD DBP 1 mm Hg 73 ± 10 95 ± 8 <0.001
Post-HD SBP 1 mm Hg 118 ± 13 132 ± 16 0.019
Post-HD DBP 1 mm Hg 71 ± 9 78 ± 11 0.081
Pre-HD SBP 2 mm Hg 136 ± 16 149 ± 18 0.059
Pre-HD DBP 2 mm Hg 78 ± 11 89 ± 8 0.009
Post-HD SBP 2 mm Hg 121 ± 16 127 ± 18 0.369
Post-HD DBP 2 mm Hg 72 ± 9 78 ± 10 0.114
 pre-HD SBP mm Hg 6.4 ± 12.8 −15.6 ± 14.2 <0.001
 pre-HD DBP mm Hg 4.5 ± 8.1 −6.5 ± 7.9 <0.001
 post-HD SBP mm Hg 2.8 ± 12.6 −4.5 ± 15.6 0.221
 post-HD DBP mm Hg 1.4 ± 11.1 −0.4 ± 11.6 0.824
SBP, systolic blood pressure; DBP, diastolic blood pressure;  BP, BP at
the end of individualized Na+ HD phase minus BP at the end of the standard
Na+ HD phase (see Methods for details). “Controlled BP” were subjects with
pre-HD BP ≤150/85 mm Hg during the control phase of the study, regardless of
use of antihypertensive drugs. “Uncontrolled BP” subjects were those with BP
>150/85 mm Hg.
trolled BP subjects. No differences in achieved weight
were noted between groups. In fact, both groups had a
minimal increase in post-HD weight as the study pro-
gressed (controlled BP patients gained 0.3 ± 0.3 kg, un-
controlled BP patients gained 0.2 ± 0.3 kg, P = 0.40).
Significant changes in IDWG occurred in patients with
uncontrolled BP (standard Na+, 3.12 ± 1.00 kg; individu-
alized Na+ 2.42 ± 0.71 kg; P < 0.001), as well as in those
with controlled BP (standard Na+, 2.65 ± 0.63 kg; indi-
vidualized Na+ 2.14 ± 0.55 kg; P = 0.007). There were
no differences in post-HD blood pressure levels in either
group.
The correlation between IDWG and the gradient be-
tween dialysate and plasma Na+ concentration in the
standard Na+ phase of the study was not significant. How-
ever, the correlation was significant when the IDWG was
adjusted to the estimated dry weight (Fig. 2).
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Fig. 1. Individual behavior of systolic BP in during control (phase 1)
and intervention (phase 2) periods according to BP control status. “Con-
trolled BP” were subjects with pre-HD BP ≤150/85 mm Hg during the
control phase of the study, regardless of use of antihypertensive drugs.
“Uncontrolled BP” subjects were those with BP >150/85 mm Hg. The
hatched line indicates 150 mm Hg, which was the cutoff used to indicate
BP control based on pre-dialysis BP. Phase 1, standard dialysate Na+
(138 mEq/L); phase 2, individualized dialysate Na+.
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Fig. 2. Correlation between the difference between dialysate and
plasma sodium (sodium gradient) and the interdialytic weight gain
adjusted to the estimated dry weight (IDWG/DW) in the standard
dialysate Na+ (138 mEq/L) phase of the study.
The plasma free water deficit at the end of the standard
HD sessions was determined by the formula:
Free water deficit = Post-HD Na
±-Pre-HD Na±
Pre-HD Na+
× total body water∗
(∗by the Watson formula) [14].
The mean postdialysis plasma free water deficit in stan-
dard Na+ HD was 0.56 ± 0.47 L.
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Fig. 3. Correlation between the free water deficit in standard dialysate
Na+ (138 mEq/L) phase and the difference between the interdia-
lytic weight gain in standard dialysate Na+ and in individualized Na+
(IDWG difference).
Table 3. HD-related hypotension, symptoms and interdialytic thirst
scores in standard Na+ HD and individualized Na+ HD
Standard Na+ Individualized Na+ P value
Hypotension 23 (9%) 6 (2%) <0.001
Cramps 12 (5%) 5 (2%) 0.072
Headaches 11 (5%) 3 (1%) 0.010
Nausea/vomiting 0 (0%) 0 (0%) –
Interdialytic thirst
Nil 0 (0%) 4 (15%) 0.043
Mild 1 (4%) 17 (63%) <0.001
Moderate 11 (41%) 5 (18%) 0.07
Severe 15 (55%) 1 (4%) <0.001
There was a significant correlation between the cal-
culated free water deficit in standard Na+ HD and the
difference between the IDWG in standard Na+ HD and
individualized Na+ HD (Fig. 3).
Dialysis-related hypotension and related symptoms
were reduced in the individualized sodium phase of
the study (Table 3). Thirst scores were also significantly
reduced.
As an “intention-to-treat” analysis, we also reviewed
the data from the group of 10 patients who were not part
of the main analysis because their plasma Na+ was not
lower than the dialysate Na+ concentration. This sub-
analysis showed no significant differences in any of the
study variables between the early and latter three-week
periods of the study. One could also look at this analysis
as one to confirm the absence of temporal confounding,
as it demonstrates the stability of this group of patients
throughout both phases of the study without any inter-
vention being applied.
DISCUSSION
In this study we analyzed the short-term consequences
of an individualized dialysate Na+ prescription in a popu-
lation of nondiabetic, nonhypotension prone, stable HD
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patients. The short-term duration permitted us to leave
unchanged important parameters, such as estimated dry
weight and the dosage of vasoactive drugs, and thereby
link the observed differences exclusively to the dialysate
sodium changes. The main findings of our study were
a reduction in IDWG, ultrafiltration, interdialytic thirst,
and an improvement in predialysis BP in hypertensive
patients.
Flanigan [10] has emphasized the importance of
sodium balance during the dialysis treatment, and the
importance of its ionic activity rather than its total con-
centration in the fluid and electrolyte movement be-
tween plasma and dialysate. We, therefore, determined
the plasma and dialysate direct sodium concentration by
direct potentiometry. Direct potentiometry permits the
determination of sodium concentration in undiluted sam-
ples, and is not influenced by abnormal levels of plasma
proteins and lipids. Furthermore, the method measures
noncomplexed, free sodium concentration, which repre-
sents those sodium molecules available for diffusion [10].
For this reason, it is proposed that sodium levels deter-
mined by direct potentiometry be referred to as the con-
centration of ionized sodium rather than total sodium
concentration [15]. To avoid clinical confusing interpre-
tation the results are usually related to flame photometry
results by a conversion factor [16].
The difference in sodium concentration between
plasma and dialysate noted by us and others [7, 17] oc-
curs because plasma water constitutes only 93% of to-
tal plasma, whereas it is 100% of total dialysate volume.
In vivo, this concentration difference is compensated by
the Gibbs-Donnan effect. Otherwise, the dialysate should
have a concentration approximately 6 to 7 mEq/L higher
to result in an isonatremic dialysis [10, 17]. The Gibbs-
Donnan effect in hemodialysis occurs because plasma
proteins, which are negatively charged and not diffus-
able through the dialysis membrane, create an electric
field that attracts sodium, reducing the plasma diffusable
sodium by 4% to 5% [17]. In our study, low dialysate
Na+ values (130 mEq/L) were observed when dialysate
Na+ concentration was measured by direct ionometry be-
cause the values were adjusted to the volume of plasma
water by the instrument. As it imitates what happens in
HD, we applied a theoretical Gibbs-Donnan effect of 0.95
to plasma Na+ concentration to better estimate the ac-
tual gradient between dialysate and plasma. Some direct
ionometry-based electrolyte analyzers provide configu-
rations that allow the determination of sodium values
in aqueous solutions, including dialysate, without a cor-
rection for the plasma water volume. In such cases,
the Gibbs-Donnan correction is not needed for plasma
sodium, and a dialysate to plasma sodium gradient may
be established directly. It is known that direct ionome-
try sodium determination in aqueous solutions may be
affected by pH and substances such as glucose [18], but
we do not believe these interactions had an impact in our
observations.
Other methods may be used to establish the actual
pre-HD dialysate to plasma sodium gradient. Dialysate
conductivity reflects ionic activity and mirrors dialysate
Na+ concentration when multiplied by 10 [19]. On-line
dialysate and plasma conductivity can be measured in HD
patients and reflects diffusible particles, mainly sodium.
In machines equipped with conductivity monitors, this
technique may be used to estimate the dialysate to pre-
HD plasma sodium gradient, and has the advantage of
allowing adjustments and matching during the dialysis
session [20].
Our results showed that predialysis sodium concentra-
tion was constant when the dialysate was set to a stan-
dard concentration, and remained at the same level when
the dialysate sodium concentration was individualized.
This is in agreement with previous studies showing that
the predialysis sodium concentration is constant indepen-
dently of the sodium gradient established between blood
and dialysate in the previous session [6]. This “set point”
dictates the interdialytic fluid intake to bring one’s osmo-
lality back to its set point; if the post-HD Na+ is higher,
greater IDWG will inevitably occur. Our data substanti-
ate this assertion.
We found a significant correlation between the
dialysate to plasma Na+ gradient and IDWG adjusted
to the estimated dry weight in the standard dialysate Na+
phase of the study. These data are in agreement with the
findings of Levin et al [7], who found the same significant
correlation between the dialysate to blood Na+ gradient
and the absolute interdialytic weight gain. Furthermore,
when we estimated the free water deficit generated by the
dialysate to plasma Na+ gradient in standard Na+ HD,
we found a significant correlation between this gradient
and the difference between the IDWG in standard Na+
HD and individualized Na+ HD. These analyses show
that part of the interdialytic fluid ingestion is destined
to supply the free water deficit generated by the higher
dialysate sodium concentration. In fact, when we adjusted
the dialysate Na+ concentration to the predialysis plasma
Na+ concentration we observed a significant reduction in
interdialytic thirst scores, IDWG, and, concomitantly, in
ultrafiltration requirements. The decrease in the rate of
fluid removal during the HD session is the most likely
cause of the observed reduction in the HD hypotension
episodes.
The main concern with the method of individualized
dialysate Na+ prescription is that, in attempting to reach
an isonatric HD, it could result in hyponatremia and
hyposmolality-related complications because of the lack
of sodium diffusion and the concomitant sodium losses
by ultrafiltration. Indeed, postdialysis Na+ plasma con-
centration was significantly reduced in the individualized
Na+ HD. However, convective sodium losses are lower
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than expected in HD, and were partially compensated
by the reduction in the ultrafiltration and were well tol-
erated. Besides, predialysis sodium remained unchanged
despite the decrease in IDWG, probably related to a de-
crease in interdialytic fluid ingestion. Therefore, we be-
lieve that the adjustment in the sodium prescription based
on predialysis values may be used safely. Another possi-
ble problem is that patients who are prone to intradialytic
hypotension may not tolerate this technique. We did not
include these patients in our study, and caution must be
exercised when extending our results to this specific group
of patients.
It could be anticipated that decreased IDWG and a
more negative Na+ balance could lead to better BP
control; however, it is well known that there is a lag
period between changes in Na+ balance and volume
status and achievement of BP control [21], so we were
surprised with our findings of improved BP control in
hypertensive patients after only three weeks of interven-
tion. Several previous studies have addressed this issue
in different ways [12, 22–24]. Flanigan et al and Song
et al have demonstrated that the use of Na+ profiling
with high time-averaged dialysate Na+ leads to higher
BP carefully documented by ambulatory BP monitoring
[22, 23]. Alternatively, Krautzig et al [12] and Ferraboli
et al [abstract; Ferraboli R et al, J Am Soc Nephrol
13:211A, 2002] showed that lowering the dialysate
sodium concentration to 135 mEq/L can be a success-
ful intervention to improve BP control, a finding that was
not corroborated by Kooman et al [24]. We did not find
a significant difference in blood pressure levels between
the two phases of the study when analyzing the group
as a whole. However, stratified analyses according to BP
control demonstrated that uncontrolled BP subjects had
a significant improvement in BP control, whereas con-
trolled BP patients remained with stable BP levels. Simi-
lar findings were reported by Flanigan et al in their study
of different sodium modeling approaches, who observed
a rise of BP in their normotensive patients, whereas hy-
pertensive patients had a usual fall in BP, especially those
who were not under pharmacologic treatment [22]. Pres-
ence or absence of drug treatment did not alter our
results; only the presence of uncontrolled BP was a
predictor of a BP-lowering response to individualized
dialysate Na+ in our study.
It does not seem that our results were caused by the
observed changes in IDWG, as there were no signifi-
cant changes in achieved weight, and both controlled BP
and uncontrolled BP patients had a significant decrease
in IDWG in the individualized Na+ HD. Individualized
dialysate prescriptions lead to a decrease in ionic mass
transfer to the patient [19], so it is possible that the indi-
vidualized prescription led to a more favorable sodium
balance and lower peripheral resistance, as has been sug-
gested in patients undergoing daily nocturnal hemodial-
ysis [25, 26]. Any further discussion on mechanisms to
explain our observations would be merely speculative.
Our study has several limitations that merit discus-
sion. First is the exclusion of hypotension-prone patients,
which certainly limits the ability to generalize our results
as discussed above. Second is the fact that we did not em-
ploy randomized block assignment to our study design, a
technique that would have strengthened our methodol-
ogy. While this is a limitation, we are reassured by the lack
of temporal changes in the group of 10 subjects excluded
from analysis due to baseline plasma Na+, an observation
that makes us confident that the differences observed in
the individualized group were indeed related to the inter-
vention, and not due to temporal changes as confounders.
Third is the issue related to the adjustment of the pre-
scribed individualized Na+ to the characteristics of our
dialysis machines, which accept adjustments in dialysate
Na+ only in even numbers. However, our analysis of the
average difference did not show a bias in either direction,
and we believe that this does not detract from our results.
Last is the fact that we did not use ambulatory BP mon-
itoring, which is a more precise method to estimate BP
in dialysis patients, as established by our own group [27].
While this is a limitation, the careful protocol observed in
the determination of peridialysis BPs makes our results
as reproducible as possible.
CONCLUSION
An individualized dialysate Na+ concentration was as-
sociated with a decrease in interdialytic thirst, IDWG,
dialysis hypotension and related-symptoms, and better
BP control in stable chronic HD patients. Long-term
studies are necessary to observe if these short-term ben-
efits are sustained.
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